Frankfurt - Delayed Quote EUR
Silence Therapeutics plc (XRP2.F)
4.5200
+0.0400
+(0.89%)
At close: 8:17:56 AM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in GBP | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 7 | 7 |
| Avg. Estimate | 3.43M | 3.43M | 18.22M | 18.56M |
| Low Estimate | 2.35M | 2.35M | 451k | 7.51M |
| High Estimate | 4.51M | 4.51M | 49.23M | 35.9M |
| Year Ago Sales | 598k | 1.14M | 34.27M | 18.22M |
| Sales Growth (year/est) | 473.75% | 200.44% | -46.83% | 1.84% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| XRP2.F | -- | -- | -- | -- |
| S&P 500 | 13.13% | 2.46% | 7.55% | 14.08% |
Upgrades & Downgrades
| Maintains | Goldman Sachs: Sell to Sell | 5/9/2025 |
| Maintains | Morgan Stanley: Overweight to Overweight | 5/9/2025 |
| Maintains | Chardan Capital: Buy to Buy | 5/9/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/7/2025 |
| Maintains | Morgan Stanley: Overweight to Overweight | 3/5/2025 |
| Maintains | BMO Capital: Outperform to Outperform | 3/4/2025 |